From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology.
Del Rosso JQ, Plattner JJ.
J Clin Aesthet Dermatol · review-article; review; journal article PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tavaborole. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
14 träffarInvestigational drugs for onychomycosis.
Gupta AK, Simpson FC.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2013.840289Current and emerging options in the treatment of onychomycosis.
Elewski B, Pariser D, Rich P, Scher RK.
Semin Cutan Med Surg · research support, non-u.s. gov't; review; journal article · DOI 10.12788/j.sder.0016An assessment of the genetic toxicology of novel boron-containing therapeutic agents.
Ciaravino V, Plattner J, Chanda S.
Environ Mol Mutagen · journal article · DOI 10.1002/em.21779New therapeutic options for onychomycosis.
Gupta AK, Simpson FC.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.681779Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing cap.
Sarkar J, Mao W, Lincecum TL, Alley MR, Martinis SA.
FEBS Lett · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.febslet.2011.08.0105-Fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol.
Madura ID, Adamczyk-Woźniak A, Jakubczyk M, Sporzyński A.
Acta Crystallogr Sect E Struct Rep Online · research-article; journal article · DOI 10.1107/s1600536811001632Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690.
Zhou XL, Tan M, Wang M, Chen X, Wang ED.
Biochem J · research support, non-u.s. gov't; journal article · DOI 10.1042/bj20100474tRNA-dependent pre-transfer editing by prokaryotic leucyl-tRNA synthetase.
Tan M, Zhu B, Zhou XL, He R, Chen X, Eriani G, Wang ED.
J Biol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1074/jbc.m109.060616Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.
Seiradake E, Mao W, Hernandez V, Baker SJ, Plattner JJ, Alley MR, Cusack S.
J Mol Biol · comparative study; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jmb.2009.04.073In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.
Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, Hold KM, Akama T, Zhang YK, Plattner JJ, Maibach HI.
J Pharm Sci · comparative study; journal article · DOI 10.1002/jps.20901AN-2690, a novel antifungal for the topical treatment of onychomycosis.
Barak O, Loo DS.
Curr Opin Investig Drugs · review; journal articleAn antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR.
Science · journal article; research support, n.i.h., extramural · DOI 10.1126/science.1142189Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ.
J Med Chem · journal article · DOI 10.1021/jm0603724